NewcelX Ltd. announced a successful FDA Pre-IND meeting regarding its NCEL-101 candidate, establishing a clear pathway toward initiating clinical trials for the treatment of Type 1 diabetes. The company intends to use the feedback from this meeting to advance its regulatory strategy. NewcelX Ltd. is a biotechnology company focused on developing therapeutic treatments.
